Customer-Centric Compounding Pharmacy
| Gross Revenue: | $2,232,000 |
| EBITDA: | $371,000 |
The offering is a customer-centric compounding pharmacy offering consultative care, complementary services such as round-the-clock refill services & prescription transfer, and over-the-counter products.
Key Aspects:
• Compounding pharmacy offering both sterile and non-sterile
services including creation of in-demand medications such as class GLP-1 agonist
• One of longest tenured compounding pharmacies within the region
• Over the counter products and prescription transfer capabilities with twenty-four hour, seven-day-a-week refill services
• Large facility with the capacity to well manage further growth
• Licensed to operate in 16 states
• Physicians the Company engages business with went from 959 in June 2023 to 1238 in June 2024
• Ownership attests sales have increased 100% from July 2023 to
July 2024 compared to previous 12 months
Opportunities
• Capitalize on the Company’s ability to compound medications classed as GLP-1 agonist, such as Ozempic & Wegovy, which are experiencing shortages amid high demand as weight loss drugs
• Focus more resources to expand the exposure of weight loss related services
• Further cross-selling opportunities with new physicians seeking compounded GLP-1 agonist medications, including other medication classes such as hormone replacement therapy (HRT)
• Expand sales & marketing outreach to additional physicians in the area
• Explore potential in the holistic health industry to pair with more natural compounding options
Headquartered
• Southwest U.S.
Current Markets
• The Company serves individuals & healthcare providers in the Southwest U.S.
Real Estate
• The Company operates from a 9,500 square foot office building in the Southwest U.S. with room for expansion. The property is owned by an affiliate entity and is expected to be leased to new ownership post-sale.
Shareholder Objectives
• The Company is fully owned by a single shareholder who seeks to exit and prepare for retirement. The owner is willing to remain with the Company for a reasonable period to facilitate a smooth transition to new ownership.
